Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow HALO
Halozyme Therapeutics, Inc. (HALO) EV/Sales
As of 16 October 2026, Halozyme Therapeutics, Inc. (HALO) trades at a EV/Sales of 9.7×. Over the past ten years it has ranged from 6.0× (June 2016) to 32.7× (June 2015); the current reading is higher than 46% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.7× | 11.83% |
| FY2024 | 6.9× | (6.63%) |
| FY2023 | 7.4× | (43.85%) |
| FY2022 | 13.2× | 0.74% |
| FY2021 | 13.1× | (43.98%) |
| FY2020 | 23.3× | 79.92% |
| FY2019 | 13.0× | 5.10% |
| FY2018 | 12.3× | 56.88% |
| FY2017 | 7.9× | (10.61%) |
| FY2016 | 8.8× | (44.43%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.7× | 6.31% |
| Mar 2026 | 6.3× | (18.70%) |
| Dec 2025 | 7.7× | 1.95% |
| Sep 2025 | 7.6× | 22.10% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| EXEL Exelixis, Inc. compare | 6.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| HALO Halozyme Therapeutics, Inc. | 9.7× |
| ASND Ascendis Pharma A/S compare | 11.6× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| BBIO BridgeBio Pharma, Inc. compare | 19.9× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)